Inpharma 1344 - 29 Jun 2002 Sulodexide for venous leg ulcers in chronic venous insufficiency Sulodexide * induces fast and effective ulcer healing in patients with venous leg ulcers due to chronic venous insufficiency, report researchers from Italy. ** In this multicentre study, 230 such patients enrolled in the venous arm of the SUAVIS † trial were randomised to receive IM sulodexide [‘Vessel Due F’] 60 mg/day for 20 days, followed by oral sulodexide 100 mg/day for 70 days (n = 120), or placebo. Sulodexide was administered in combination with local compression bandaging. At 2 months, a significantly greater proportion of patients who received sulodexide, compared with placebo recipients, had completely healed ulcers (35 vs 20.9%). The results were consistent at 3 months (52.5 vs 32.7%, respectively). The time course of changes to ulcer surface areas was significant for treatment with sulodexide, but not placebo. Ulcers of ≤ 10cm 2 and of relatively recent onset (≤ 12 months) were most likely to heal after treatment with sulodexide, compared with after placebo treatment. * Alfa Wassermann, Keryx Biopharmaceuticals; phase II for diabetic nephropathies and kidney disorders ** Two of the researchers were affiliated with Alfa Wassermann, Italy. † SUAVIS = Sulodexide Arterial Venous Italian Study Coccheri S, et al. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thrombosis and Haemostasis 87: 947-952, May 2002 800912109 1 Inpharma 29 Jun 2002 No. 1344 1173-8324/10/1344-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Sulodexide for venous leg ulcers in chronic venous insufficiency

Download PDF Report

View
222
Download
4

Embed Size (px)

Citation preview

Inpharma 1344 - 29 Jun 2002

Sulodexide for venous leg ulcers inchronic venous insufficiency

Sulodexide* induces fast and effective ulcer healing inpatients with venous leg ulcers due to chronic venousinsufficiency, report researchers from Italy.**

In this multicentre study, 230 such patients enrolledin the venous arm of the SUAVIS† trial were randomisedto receive IM sulodexide [‘Vessel Due F’] 60 mg/day for20 days, followed by oral sulodexide 100 mg/day for 70days (n = 120), or placebo. Sulodexide wasadministered in combination with local compressionbandaging.

At 2 months, a significantly greater proportion ofpatients who received sulodexide, compared withplacebo recipients, had completely healed ulcers (35 vs20.9%). The results were consistent at 3 months (52.5 vs32.7%, respectively). The time course of changes toulcer surface areas was significant for treatment withsulodexide, but not placebo. Ulcers of ≤ 10cm2 and ofrelatively recent onset (≤ 12 months) were most likely toheal after treatment with sulodexide, compared withafter placebo treatment.* Alfa Wassermann, Keryx Biopharmaceuticals; phase II for diabeticnephropathies and kidney disorders** Two of the researchers were affiliated with Alfa Wassermann, Italy.† SUAVIS = Sulodexide Arterial Venous Italian Study

Coccheri S, et al. Randomised, double blind, multicentre, placebo controlled studyof sulodexide in the treatment of venous leg ulcers. Thrombosis and Haemostasis87: 947-952, May 2002 800912109